ClinicalTrials.gg
Active, not recruitingNCT05685238FRONTIER4Updated Sep 9, 2026

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

A Phase 3 interventional study of Mim8 in Haemophilia A and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S. Active, not recruiting at 141 sites in 32 countries. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Planned enrollment
Largest of 59
451 · median 38
Started
2023
with 2 others
Phase 3
21 of 92
1 open now
Primary completion
2028-06
later than 8 of 11 live
Registered
81st of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one has the largest planned enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2023, is one of 21 in phase 3, reaches primary completion later than 8 of the 11 other live ones, and was the 81st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the study will end in June 2028, whichever comes first. Participants will get up to 262 injections; the number of injections depends on how often participants will get injections and how long time participants take part in the study. While taking part in this study, there are some restrictions about what medicine participants can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.

03

Conditions studied

  • Haemophilia A
  • Haemophilia A With Inhibitors

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Arm 1 \& 2:

Inclusion Criteria:

  1. obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  2. Male or female with diagnosis of congenital haemophilia A based on medical records.
  3. Ongoing participation in study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728 at the time of transfer. Participant should qualify either of the following criteria:

    1. Participant from study NN7769-4513, who has participated in the extension part of the study for at least 12 weeks prior to enrolment in study NN7769-4532, or,
    2. Participant has completed the end of treatment visit for study NN7769-4514, NN7769-4516 or NN7769-4728.
  4. Participant and/or participant's parent(s)/participant's Legally acceptable representative (LAR) willingness and ability to comply with scheduled visits and study procedures, including the completion of diary.

Exclusion Criteria:

  1. Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  2. Participant who has discontinued or been withdrawn from studies NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728.
  3. Previous participation in this study. Participation is defined as signed informed consent.
  4. Female who is pregnant, breast-feeding or intends to become pregnant.
  5. Female of and not using a highly effective method (highly effective contraceptive measures or as required by local regulation or practice).
  6. Participation (i.e., signed informed consent) in any interventional, clinical study (except from study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728) of an approved or non-approved medicinal product.
  7. Any planned major surgery, during part 1 of the study.
  8. Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.

Arm 3:

Inclusion criteria

  1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  2. Male or female with diagnosis of congenital severe haemophilia A (endogenous FVIII activity less than (\<) 1 percentage [%]) with or without FVIII inhibitors based on medical records.
  3. Aged \<1 year at the time of signing informed consent.
  4. Body weight greater than or equal to (≥) 3.2 kilograms at the time of signing informed consent.
  5. previously untreated patients (PUPs) or minimally treated patients (MTPs) (i.e., up to 5 days of exposure to haemophilia-related treatment such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products).
  6. Full-term pregnancy (gestational age ≥37 weeks).
  7. Participant's parent(s)/LAR(s) willingness and ability to comply with scheduled visits and Arm 3 (infant) procedures, including the completion of diary and patient reported outcome (PRO) questionnaire.
  8. Participants \<3 months of age must show no signs of active intracranial haemorrhage at screening. This is confirmed by cranial ultrasound performed according to local practice and regardless of delivery method.
  9. Receipt of vitamin K prophylaxis (as per local standard practice).
  10. Availability of historical results in medical records for:

    1. (aPTT)
    2. FVIII levels.
  11. Availability of historical results in medical records or pre-dose sample taken for:

    1. fibrinogen
    2. haematology parameters
    3. biochemistry parameters ( (AST) and/or alanine aminotransferase (ALT), and creatinine).

Exclusion criteria

  1. Known or suspected to trial product or related products.
  2. Previous participation in study 4532. Participation is defined as signed informed consent.
  3. Participation (i.e., signed informed consent) in any interventional clinical study with receipt of the last dose within 6 months (or 5 half-lives of the investigational medicinal product, whichever is shorter) before planned enrolment.
  4. Exposure to non-factor haemostatic products for bleeding prophylaxis within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned enrolment.
  5. Known congenital or acquired coagulation disorders other than haemophilia A.
  6. Other conditions (e.g., disease) or laboratory abnormality that may increase the risk of bleeding or thrombosis, as evaluated by the investigator. Any disorder, except for conditions associated with haemophilia A, that in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
  7. Lack of adequate parental/legally acceptable representative (LAR) support to enter accurately and timely information regarding treatment and bleeding episodes into an (electronic) diary.
  8. Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease.
  9. Any planned major surgery, during part 1 of Arm 3 (infant). For definition of major surgery.
  10. Immune tolerance induction planned to take place after treatment initiation.
  11. Hepatic dysfunction defined as AST and/or ALT greater than (>) 3 times the (ULN) combined with total bilirubin >1.5 times the ULN.
  12. Serum creatinine above 1.5 times the ULN.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
451 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Participants entering from the multiple ascending dose (MAD) part of study NN7769-4513. In part 1, participants will receive Mim8 prophylaxis (PPX) subcutaneous (s.c.) administration using enhanced cartridge for 26 weeks. In part 2, participants will receive Mim8 PPX s.c. administration using enhanced cartridge or DV3407 pen-injector once it is approved.

    Drug: Mim8

  • Experimental
    Arm 2

    Participants entering from study NN7769-4514, NN7769-4728 and NN7769-4516. In part 1, participants will receive Mim8 PPX s.c. administration using DV3407 pen-injector for 26 weeks. In part 2, participants will receive Mim8 PPX s.c. administration using DV3407 pen-injector.

    Drug: Mim8

  • Experimental
    Arm 3

    In part 1 and 2, participants will receive Mim8 PPX s.c. administration using DV3407 pen-injector.

    Drug: Mim8

Interventions

  • DrugMim8

    Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 and 3 will use the DV3407 pen injector.

06

What researchers measure

Primary outcomes

  1. Arm 1 and 2: Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From week 0 until end of study (up to 283 weeks)

  2. Arm 3: Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From treatment initiation (week 0) until end of study (up to 124 weeks)

Secondary outcomes

  1. Arm 1 and 2: Number of injection site reactions

    Measured as count of reactions.

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  2. Arm 1 and 2: Occurrence of anti Mim8 antibodies

    Measured as count of participants.

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  3. Arm 1 and 2: Number of treated bleeding episodes

    Measured as count of bleeds.

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  4. Arm 1 and 2: Number of treated spontaneous bleeding episodes

    Measured as count of bleeds.

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  5. Arm 1 and 2: Number of treated traumatic bleeding episodes

    Measured as count of bleeds.

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  6. Arm 1 and 2: Number of treated joint bleeding episodes

    Measured as count of bleeds.

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  7. Arm 2: Number of treated target joint bleeding episodes

    Measured as count of bleeds.

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  8. Arm 1 and 2: Mim8 plasma concentration

    Measured as micrograms per milliliter (µg/mL).

    Time frame: From week 0 until end of treatment (up to 262 weeks)

  9. Arm 2: Device handling using haemophilia device assessment tool (HDAT) (applicable for participants in arm 2 only)

    Measured as percentage of participants.

    Time frame: From week 26 until end of treatment (up to 262 weeks)

  10. Arm 3: Number of injection site reactions

    Measured as count of reactions.

    Time frame: From treatment initiation (week 0) until end of treatment (up to 103 weeks)

  11. Arm 3: Occurrence of anti Mim8 antibodies

    Measured as count of participants.

    Time frame: From treatment initiation (week 0) until end of treatment (up to 103 weeks)

  12. Arm 3: Number of treated bleeding episodes

    Measured as count of bleeds.

    Time frame: From treatment initiation (week 0) until end of treatment (up to 103 weeks)

  13. Arm 3: Number of treated spontaneous bleeding episodes

    Measured as count of bleeds.

    Time frame: From treatment initiation (week 0) until end of treatment (up to 103 weeks)

  14. Arm 3: Number of treated traumatic bleeding episodes

    Measured as count of bleeds.

    Time frame: From treatment initiation (week 0) until end of treatment (up to 103 weeks)

  15. Arm 3: Mim8 plasma concentration

    Measured as µg/mL.

    Time frame: From treatment initiation (week 0) until end of treatment (up to 103 weeks)

  16. Arm 3: Device handling using haemophilia device assessment tool (HDAT)

    Measured as percentage of participants.

    Time frame: At week 26 and week 52

07

Study locations

141 sites

Showing the first 100 of 141 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Matsushita T, Banchev A, Bovet J, Chowdary P, Garcia Fernandez LM, Jimenez-Yuste V, Kavakli K, Kremer Hovinga JA, Windyga J, Young G. Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER. Blood Adv. 2026 Jul 17:bloodadvances.2025019095. doi: 10.1182/bloodadvances.2025019095. Online ahead of print. PubMed 42469164 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jun 2028, 64 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 64 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 17, 2023
StartActual
Feb 13, 2023
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05685238
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Feb 13, 2023
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 9, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denecimig

Start the discussion